Replies to post #593889 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I’ve been following Poly iclc and UCLA’s publications on it for about a decade. I know it’s important.

The current spore trial does not minimize its importance.

Poly iclc has several MOAs.

Poly ICLC May or may not already be commercially approved as an adjuvant for squamous cell cancer. (Hopefully someone will get to the bottom of that and find out which regulatory agency, what’s it an adjuvant to, and what subset of squamous cell cancer)

Dr. Liau has stated, in no uncertain terms, in October 2022, that the spore trial started with DCVax-l and Keytruda, and they intend on adding, apparently one at a time, Poly-iclc and csf1r, in that order to the aforementioned duo within the trial.